SpecificityThe antibody reacts with human natural and recombinant IL-6 as assessed by ELISA. The antibody inhibits the biological activity of human natural and recombinant IL-6 as determined with the B9 cell bio-assay.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesThe antibody is useful for inhibition of human and monkey IL-6 in bio-assays. Furthermore the antibody is useful for staining of IL-6 in Western blots. Before use in biological assays, the product must be filter sterilized and depending on the concentration to be used dialysed against culture medium to remove the sodium azide added. Dilutions have to be made according to the amount of IL-6 to be inactivated. For Western blots the material should be diluted 20 times.
FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Sequence similaritiesBelongs to the IL-6 superfamily.
Post-translational modificationsN- and O-glycosylated.